The significance of serum lysozyme in predicting bacterial complications in patients after kidney transplantation

The aim of the study was to conduct a comparative analysis of serum lysozyme activity and study its innovativeness in predicting bacterial complications after kidney transplantation. Material and methods. Lysozyme activity was studied in 99 patients after kidney transplantation and 81 practically healthy volunteers. Patients depending on period after surgery were divided into five groups: group 1 – 1st day after kidney transplantation (n = 6); group 2 – 1–5 months (n = 10); group 3 – 6–12 months (n = 21); group 4 – 2–5 years (n = 30); group 5 – 6–10 years (n = 32). An analysis of the correlation between serum lysozyme level, absolute leukocyte count and creatinine content was performed. Lysozyme activity was assessed in bacterial complications, transplant dysfunction and organ rejection. Results and discussion. On the 1st day after kidney transplantation lysozyme activity was minimal – 117.95 [60.80–133.51] µg/ ml (median [lower quartile – upper quartile]) (in healthy volunteers it was 243.80 [190.76–305.69] µg/ml, p < 0,001). One month after surgery, it returned to normal (292.08 [311.66–218.48] μg/ml) and did not differ from the value of the group of practically healthy volunteers for 5 months (p = 0,17). Lysozyme activity in serum of patients after kidney transplantation had inverse moderate correlation with creatinine content (r = –0,32, p < 0,05). The threshold value for the probability of bacterial infections for serum lysozyme was > 321,4 μg/ml (p = 0,003). Creatinine level > 0,11 mmol/l predicts graft dysfunction. Conclusions. On the first day after transplantation a low level of lysozyme indicates high risk of bacterial infection. One month after surgery lysozyme returned to normal which indicates restoration of humoral component of nonspecific immune resistance. Relationship between creatinine content and lysozyme activity as well as an increase in the latter in comparison with healthy group allows to use lysozyme as an additional diagnostic criterion for acute bacterial infection and creatinine – for prognosis of graft dysfunction.

1. Voora S., Adey D.B. Management of kidney transplant recipients by general nephrologists: core curriculum 2019. Am. J. Kidney Dis. 2019;73(6):866–879. doi: 10.1053/j.ajkd.2019.01.031

2. Liu R., Meng Q., Dai Y., Zhang Y. Structure and function of human-derived lysozyme: a review. Sheng Wu Gong Cheng Xue Bao. 2023;39(11):4482–4496. doi: 10.13345/j.cjb.230241

3. Pankratov T.A., Gannesen A.V., Nikolaev Y.A. Regulation of lysozyme activity by human hormones. Iran. Biomed. J. 2023;27(1):58–65. doi: 10.52547/ibj.3614

4. Wu T., Jiang Q., Wu D., Hu Y., Chen S., Ding T., Ye X., Liu D., Chen J. What is new in lysozyme research and its application in food industry? (A review). Food Chem. 2019;274:698–709. doi: 10.1016/j.foodchem.2018.09.017

5. Benachour A., Ladjouzi R., le Jeune A., Hébert L., Thorpe S., Courtin P., Chapot-Chartier M.P., Prajsnar T.K., Foster S.J., Mesnage S. The lysozyme-induced peptidoglycan N-acetylglucosamine deacetylase PgdA (EF1843) is required for Enterococcus faecalis virulence. J. Bacteriol. 2012;194 (22):6066–6073. doi: 10.1128/JB.00981-12

6. Ziamko V., Okulich V., Dzyadzko A. Some promising opportunities of using lysozyme as a humoral factor of the immune system in diagnostics and treatment. Khirurgiya. Vostochnaya Yevropa = Surgery. Eastern Europe. 2019; 8 (3):376–387. [In Russian].

7. Ferraboschi P., Ciceri S., Grisenti P. Applications of lysozyme, an innate immune defense factor, as an alternative antibiotic. Antibiotics (Basel). 2021;10(12):1534. doi: 10.3390/antibiotics10121534

8. Ragland S.A., Criss A.K. From bacterial killing to immune modulation: Recent insights into the functions of lysozyme. PLOS Pathogens. 2017;13(9):e1006512. doi: 10.1371/journal.ppat.1006512

9. Benítez-Páez A., Belda-Ferre P., Simón-Soro A., Mira A. Microbiota diversity and gene expression dynamics in human oral biofilms. BMC Genomics. 2014;15:311. doi: 10.1186/1471-2164-15-311

10. Arzumanyan V.G., Ozhovan I.M., Polishchuk V.B., Kostinov M.P., Ryzhov A.A., Blagovidov D.V. Antimicrobial activity of serum of cystic fibrosis patients before and after lung transplantation. Pulmonologiya = Russian Pulmonology Journal. 2022;32(2):226–231. [In Russian]. doi: 10.18093/0869-0189-2022-32-2-226-231

11. Kip A.M., Ceulemans L.J., Hundscheid I.H.R., Canovai E., Hartog H., Brown R.M., Corcos O., Joly F., de Hertogh G., Gupte G., … Lenaerts K. Paneth cell alterations during ischemia-reperfusion, follow-up, and graft rejection after intestinal transplantation. Transplantation. 2020;104(9):1952–1958. doi: 10.1097/TP.0000000000003257

12. Schmidt P., Kopsa H., Balcke P., Zazgornik J., Pils P., Hysek H. Behaviour of serum and urinary lysozyme after renal transplantation. Wien. Klin. Wochenschr. 1977;89(7):238–242. [In German].

13. Santoriello D., Andal L.M., Cox R., d‘Agati V.D., Markowitz G.S. Lysozyme-induced nephropathy. Kidney Int. Rep. 2016;2(1):84–88. doi: 10.1016/j.ekir.2016.09.002

14. Okulich V.K., Zemko V.Yu., Goncharova A.I., Dzyadzko A.M. Method for determining the activity of lysozyme: Instructions for use. Vitebsk–Minsk, 2018. 6 p. [In Russian].

15. Petri A., Sabin K. Visual medical statistics: Textbook. Moscow: GEOTAR-Media, 2021. 232 p. [In Russian].

16. Sultanov P.K., Khadjibaev F.A., Ergashev D.N., Ismatov A.A. Analysis of complications after kidney transplantation. Vestnik ekstrennoy meditsiny = Emergency Medicine Bulletin. 2021;14(1):55–64. [In Russian].